Avibactam prodrug - Pfizer
Alternative Names: ARX-1796; AV 006; AVI-ARXLatest Information Update: 14 May 2026
At a glance
- Originator Arixa Pharmaceuticals
- Developer Pfizer
- Class Amides; Antibacterials; Heterocyclic bicyclo compounds; Small molecules; Sulfates
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Gram-negative infections
Most Recent Events
- 14 May 2026 Discontinued - Phase-I for Gram-negative infections in USA (PO) (Pfizer pipeline, May 2026)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Gram-negative-infections in USA (PO)
- 22 Oct 2020 Arixa Pharmaceuticals has patent protection for prodrugs covering broad composition of matter patent (Arixa Pharmaceuticals pipeline, October 2020)